Selinexor treatment for diffuse large B-cell lymphoma with multidrug-resistant central nervous system recurrence: a case report and literature review
-
摘要: 弥漫大B细胞淋巴瘤是一种来源于成熟B细胞的侵袭性肿瘤，是最常见的非霍奇金淋巴瘤类型，占全部非霍奇金淋巴瘤的25%~50%。尽管一线治疗有效率50%以上，但仍有部分患者复发后生存期短。塞利尼索是全球首款选择性核输出蛋白抑制剂，选择性作用于XPO1靶点，已被批准用于复发难治多发性骨髓瘤、弥漫大B细胞淋巴瘤的治疗。我中心应用塞利尼索治疗1例多药耐药中枢复发的弥漫大B细胞淋巴瘤患者，该患者经一线治疗疾病完全缓解后出现中枢神经系统复发，经多线治疗后疾病仍进展且呈现多药耐药，给予其塞利尼索挽救治疗。现将患者治疗后的疗效和生存情况进行总结。Abstract: Diffuse large B-cell lymphoma(DLBCL) is an aggressive tumor derived from mature B cells and is the most common type of non-Hodgkin lymphoma, accounting for about 25%-50% of all non-Hodgkin lymphoma. Although the response rate of first-line therapy is more than 50%, some patients will have short survival after relapse. Selinexor is the world's first selective nuclear export inhibitor, which selectively binds to the XPO1 target and has been approved for the treatment of relapsed and refractory multiple myeloma and DLBCL. We recently used selinexor to the treatment of a patient with multidrug-resistant and central nervous recurrent DLBCL. The patient experienced central nervous system recurrence after complete remission from the first-line treatment. The disease still progressed and showed multidrug resistance through multi-line treatments. The patient received selinexor as the salvage therapy. Here is a summary of the patient's efficacy and survival after treatment.
-
-
[1] Cwynarski K, Cummin T, Osborne W, et al. Management of secondary central nervous system lymphoma[J]. Br J Haematol, 2023, 200(2): 160-169. doi: 10.1111/bjh.18539
[2] Cheson BD, Nowakowski G, Salles G. Diffuse large B-cell lymphoma: new targets and novel therapies[J]. Blood Cancer J, 2021, 11(4): 68. doi: 10.1038/s41408-021-00456-w
[3] 李娟, 侯健, 蔡真, 等. 塞利尼索在多发性骨髓瘤临床应用的专家共识(2022)[J]. 临床血液学杂志, 2022, 35(9): 605-611. https://lcxy.whuhzzs.com/article/doi/10.13201/j.issn.1004-2806.2022.09.001
[4] Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma[J]. N Engl J Med, 2021, 384(9): 842-858. doi: 10.1056/NEJMra2027612
[5] Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index(NCCN-IPI)for patients with diffuse large B-cell lymphoma treated in the rituximab era[J]. Blood, 2014, 123(6): 837-842. doi: 10.1182/blood-2013-09-524108
[6] 俞文娟, 曹利红, 王敬瀚, 等. 弥漫大B细胞淋巴瘤患者蛋白表达检测的预后意义[J]. 中华血液学杂志, 2017, 38(9): 784-788. https://www.cnki.com.cn/Article/CJFDTOTAL-YJZY202004023.htm
[7] 周沙, 曾韫璟, 刘红云, 等. 新药在原发中枢神经系统淋巴瘤诱导和维持治疗的诊疗体会[J]. 临床血液学杂志, 2022, 35(9): 680-684. https://lcxy.whuhzzs.com/article/doi/10.13201/j.issn.1004-2806.2022.09.015
[8] Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial[J]. Lancet, 2009, 374(9700): 1512-1520. doi: 10.1016/S0140-6736(09)61416-1
[9] NCCN Clinical Practice Guidelines in Oncology-B-Cell Lymphomas(2023 Version 2)[EB/OL].
https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.2023.05 .[10] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)淋巴瘤诊疗指南2023[M]. 北京: 人民卫生出版社, 2023: 32-33.
[11] Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma(SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial[J]. Lancet Haematol, 2020, 7(7): e511-e522. doi: 10.1016/S2352-3026(20)30120-4
[12] Maerevoet M, Zijlstra JM, Follows G, et al. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study[J]. J Hematol Oncol, 2021, 14(1): 111. doi: 10.1186/s13045-021-01122-1
[13] Zijlstra JM, Follows G, Casasnovas RO, et al. The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study[J]. Cancers(Basel), 2022, 14(3): 791.
[14] Maerevoet M, Casasnovas O, Cartron G, et al. Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final Results of 18 Patients Treated at RP2D of selinexor in the Selinda Phase Ⅰb Lysa Study[C]. 2022 ASH abstract #2948.
[15] Seymour EK, Khan HY, Li Y, et al. Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase Ⅰ Study[J]. Clin Cancer Res, 2021, 27(12): 3307-3316. doi: 10.1158/1078-0432.CCR-20-4929
[16] Kasamon YL, Price LSL, Okusanya OO, et al. FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma[J]. Oncologist, 2021, 26(10): 879-886. doi: 10.1002/onco.13859
[17] Bobillo S, Abrisqueta P, Carpio C, et al. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement[J]. Haematologica, 2018, 103(2): e92-e93. doi: 10.3324/haematol.2017.181636
[18] Rosebeck S, Alonge MM, Kandarpa M, et al. Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor[J]. Mol Cancer Ther, 2016, 15(1): 60-71. doi: 10.1158/1535-7163.MCT-15-0488
[19] Stephens DM, Huang Y, Ruppert AS, et al. Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase Ⅰ Study[J]. Clin Cancer Res, 2022, 28(15): 3242-3247. doi: 10.1158/1078-0432.CCR-21-3867
[20] Ben-Barouch S, Kuruvilla J. Selinexor(KTP-330)-a selective inhibitor of nuclear export(SINE): anti-tumor activity in diffuse large B-cell lymphoma(DLBCL)[J]. Expert Opin Investig Drugs, 2020, 29(1): 15-21.
[21] Varma G, Goldstein J, Advani RH. Novel agents in relapsed/refractory diffuse large B-cell lymphoma[J]. Hematol Oncol, 2023, 41(Suppl 1): 92-106.
-
计量
- 文章访问数: 1564
- PDF下载数: 775
- 施引文献: 0
下载: